Pediatric Hematology/Oncology Research

I am a pediatric oncologist who specializes in the treatment of children and young adults with sarcomas and other solid tumors. My research focuses on better understanding the biology of bone sarcomas in children and new strategies for the treatment of relapsed pediatric sarcomas. In addition, I am evaluating new drugs and new ways to deliver anticancer drugs, such as inhaled chemotherapy for sarcomas in the lung and clinical trials testing novel immune modulators for pediatric bone cancers. I participate in the design and implementation of clinical trials and collaborate with basic science investigators to translate their findings into new therapies for difficult to treat pediatric cancers. Recent clinical projects include using newly acquired genomic information to design individualized therapy for pediatric sarcoma patients. I also serve as the institutional (WCM) principal investigator for the Children’s Oncology Group, and direct our pediatric oncology research efforts here at WCM.

For more information, see Dr. Chou's VIVO page.

Dr. Nitya Gulati is a pediatric hematologist–oncologist at New York‑Presbyterian Hospital and Weill Cornell Medical College with a primary research focus on understanding disease biology and developing novel therapeutic strategies in pediatric histiocytic disorders and lymphomas.  Dr. Gulati received her medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India, completed pediatric residency at SUNY Downstate Medical Center, and pursued pediatric hematology–oncology fellowship training at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. Dr. Gulati subsequently completed advanced fellowship training in pediatric lymphoma and histiocytosis at Texas Children’s Hospital/Baylor College of Medicine.

Dr. Gulati serves as Vice‑Chair of the Children’s Oncology Group Langerhans Cell Histiocytosis(LCH) clinical trial for children with relapsed/refractory LCH. Ongoing work encompasses molecular risk stratification in LCH, in‑depth characterization of somatic mutations, investigation of disease natural history and development of global treatment guidelines for non‑LCH histiocytic disorders, as well as efforts to refine risk‑adapted therapies. Dr. Gulati also maintains a focused research interest in pediatric lymphoma, particularly the tumor microenvironment and mechanisms of treatment resistance in pediatric Primary mediastinal B-cell lymphomas and Hodgkin lymphoma. Dr. Gulati’s work has been supported by multiple institutional and national awards, including the Robert A. Winn Excellence in Clinical Trials Career Development Award and Hyundai Hope on Wheels.

For more information, see Dr. Gulati's VIVO page.

Dr. Shipra Kaicker is an Associate Professor of Clinical Pediatrics and an Attending Physician at New York-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Kaicker completed her medical school training at the University of Delhi, India (1991). She completed her pediatric residency at the University of Delhi (1995), and a second pediatric residency in the U.S at New York Medical College (Saint Vincent’s Medical Center). After completing a fellowship in Pediatric Hematology Oncology at Columbia University College of Physicians and Surgeons in New York in 2003, Dr. Kaicker worked as an attending Pediatric Hematologist Oncologist and full-time faculty member at the Maimonides Medical Center in Brooklyn, NY (2003-2015) and at Saint Joseph’s Medical Center, Paterson, New Jersey (2015-2017). Dr. Kaicker joined Weill Cornell Medicine as full-time faculty in 2017. She leads the Pediatric Platelet Disorders Program and the Pediatric Sickle Cell Program in the Division of Pediatric Hematology Oncology at New York-Presbyterian Hospital/Weill Cornell Medical Center.

Her clinical and translational research interests focus on pediatric platelet disorders, immunohematology, and pediatric immune cytopenias- pediatric ITP, Evans Syndrome, and Autoimmune Hemolytic Anemia. Her research focuses on identifying germline variants in genes associated with Inborn Errors of Immunity (IEI) in children with immune cytopenias to identify targeted treatment. She is actively involved in national cooperative groups and investigator-initiated research to advance the care of children with immune cytopenias. She is also involved in clinical research and in the investigation of new therapies for children with sickle cell disease at Weill Cornell Medicine.

For more information, see Dr. Kaicker’s VIVO page.

Dr. Nicole Kucine is a Professor of Clinical Pediatrics at Weill Cornell Medicine. She received her medical degree from SUNY Downstate Medical Center followed by a residency and Chief Resident year at Robert Wood Johnson University Hospital/Bristol-Myers Squibb Children’s Hospital. After completing her fellowship in pediatric hematology/oncology at the combined program of Memorial Sloan Kettering Cancer Center/NYP-Weill Cornell Medicine in 2010, she served as a special research fellow for one year and then joined the faculty at WCM in 2011. Dr. Kucine has a special research interest in pediatric myeloproliferative neoplasms (MPNs) and is an international leader in this area; she directs a unique pediatric MPN program at Weill Cornell Medicine. Dr. Kucine also works in the area of thrombosis in children in various settings (including children with cancer or inflammatory bowel disease), and she directs the Bloom syndrome registry at WCM.  

For more information, see Dr. Kucine's VIVO page.

Dr. Catherine McGuinn is currently an Associate Professor of Clinical Pediatrics at Weill Cornell Medicine (WCM) in the Division of Pediatric Hematology/Oncology. Dr. McGuinn’s research focus in research is closely linked to my clinical niche with an emphasis on expanding early and later phase clinical trials and collaborative research studies to improve the outcome of patients with hemophilia and bleeding disorders. Dr. McGuinn is the Director of the federally designated Weill Cornell - New York Presbyterian Hospital Hemophilia Treatment Center (HTC) and since joining the faculty of Weill Cornell Medicine in 2011, has been working to build the program in bleeding disorders through contributions including leadership of the clinical trials program focus on innovative therapies, cooperative group studies participation to improve clinical care and an educational commitment to train leaders in benign hematology.  Dr. McGuinn is the site PI on multi-center collaborative clinical trials focused on Phase I – Phase III therapeutic drug development and registration trials for Hemophilia including gene therapy and the institutional PI for collaborative projects with the US HTC Network (USHTCN), the American Thrombosis and Hemostasis Network (ATHN) and the Center for Disease Control (CDC) focused on bleeding disorders. 

For more information, see Dr. McGuinn's VIVO page.

Dr. Jaclyn Rosenzweig is an Assistant Professor in the Division of Pediatric Hematology/Oncology at Weill Cornell Medicine. She received her medical degree from University of Miami Miller School of Medicine followed by a residency in Pediatrics at Weill Cornell Medicine. She then completed a fellowship in Pediatric Hematology and Oncology at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, after which she became an Instructor at Memorial Sloan Kettering Cancer Center to continue her research in the Kung Lab, evaluating the use of an LSD1 inhibitor in pediatric relapsed and refractory acute myeloid leukemia in preclinical models. She joined the Division of Pediatric Hematology/Oncology at Weill Cornell Medicine in 2023. Her research interests include identifying new targeted therapies for pediatric hematologic malignancies and improving supportive care for pediatric patients with hematologic malignancies. 

For more information, see Dr. Rosenzweig's VIVO page. 

Dr. Sujit Sheth is the Director of the Division of Pediatric Hematology/Oncology at Weill Cornell Medical College and an Associate Attending Pediatrician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He is board-certified in pediatric hematology/oncology, and is an expert in iron metabolism, thalassemia, and sickle cell disease. Dr. Sheth completed his medical training at the University of Bombay, receiving his medical degree (MBBS) in 1988 and completing his resident specialty training in Pediatrics (MD) in 1991. A year later, he entered Columbia University, College of Physicians & Surgeons as a Post-Doctoral Fellow in Pediatric Hematology/Oncology, completing his fellowship in 1995 and his obligatory additional year of residency in Pediatrics in 1996. Following his residency, Dr. Sheth joined the Columbia University faculty as Assistant Professor of Pediatrics. He assumed responsibility as Clinical Director of the Pediatric Hematology program, and was promoted to Associate Clinical Professor of Pediatrics in 2004. He moved to Weill Cornell in 2011, to lead the Division of Pediatric Hematology and Oncology, was promoted to Professor of Clinical Pediatrics in 2012, and appointed the Harold Weil Professor in Pediatric Hematology in 2014. He is the Director of the New York Comprehensive Thalassemia Program, the largest single center program in the US.

For more information, see Dr. Sheth's VIVO page.